Ebola continues to ravage the Democratic Republic of Congo, with child mortality rates climbing sharply amid a worsening outbreak in the war-torn province of Ituri. According to the UN Children’s Fund, more than 300 children have died from the virus since mid-May, despite ongoing efforts to curb its spread. The situation has deepened fears among local communities, where women and children account for approximately 80 percent of the displaced population due to ongoing conflict. The UN Office for the Coordination of Humanitarian Affairs reports that the outbreak is significantly undermining essential healthcare services, with usage dropping by over 40 percent in the hardest-hit regions. This decline has left vulnerable populations, especially pregnant women, increasingly exposed to life-threatening complications. The crisis has placed immense pressure on already strained health systems, exacerbating risks for expectant mothers. The UNFPA warns that maternal deaths in Ituri have nearly doubled since the outbreak began, with roughly six women dying weekly from childbirth-related issues. Compounding these dangers is the high rate of fetal loss linked to Ebola infections during pregnancy. To address these challenges, the Congolese health ministry, alongside organizations such as the World Health Organization, UNICEF, and the Africa Centres for Disease Control, has mobilized 13,000 community workers. These volunteers have engaged with over 2.4 million residents, providing critical information on prevention and early detection. Their efforts include conducting more than 500,000 home visits aimed at dispelling myths and encouraging timely medical intervention. Amid the growing humanitarian emergency, scientific progress offers cautious optimism. A newly released report by the World Health Organization’s Technical Advisory Group recommends evaluating the existing Ebola vaccine, Ervebo, in a randomized clinical trial for the Bundibugyo virus. Preliminary animal study data suggests the vaccine might provide some cross-protection against the Bundibugyo strain, though further evidence is required before definitive conclusions can be drawn. The recommendation follows a series of assessments conducted by the group, which initially advised against using Ervebo outside controlled research environments. However, following additional findings, the panel concluded that the vaccine poses no safety concerns for use in contact tracing scenarios, where individuals exposed to confirmed cases receive immunization. The push for a potential breakthrough in treatment coincides with broader geopolitical shifts in the region. As U.S. aid to Africa has declined under the Trump administration, China has intensified its involvement in the DRC’s Ebola response. Over the past month alone, three Chinese medical teams have arrived in the country, marking a significant expansion of Beijing’s engagement. The latest contingent, which landed in Kinshasa, includes specialists trained to assist with containment efforts. With more than 3,400 cases and over 1,600 deaths reported since late May, the DRC faces an unprecedented challenge. The outbreak is primarily concentrated in Ituri, where nearly 90 percent of cases have been documented, but outbreaks have also surfaced in other parts of the country, including the large urban center of Kisangani. China’s increased presence reflects both humanitarian intent and strategic ambition. Analysts suggest the country is leveraging its medical expertise to bolster its influence in Central Africa, challenging traditional Western dominance in regional affairs. Beijing has pledged additional financial support, including $2.5 million allocated to the African Union’s Ebola response initiatives. Meanwhile, the U.S. has focused on securing its borders through strict travel restrictions and the establishment of a quarantine facility in Kenya. Despite these measures, the outbreak has complicated diplomatic efforts to stabilize the region, highlighting the interconnected nature of public health and geopolitics. As the situation evolves, the balance between immediate relief and long-term stability remains precarious.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.
Become a Supporter
United States
